drug
vopimetostat
Phase 2updated 6mo agoby $TNGX Tango Therapeutics, Inc.
Phase 2community read0 votes
indications
indications
NSCLC
all catalysts(0)
nothing on the calendar yet
News(6)
- This week in charts: ESMO’s winners and losersThe latest installment in BioPharma Dive’s visualization-focused series looks at Wall Street’s response to a trio of closely watched presentations at a top meeting for cancer drugs.biopharma_dive · 17d ago
- ESMO: Tango trims headcount after impressing analysts with ‘highly synergistic’ RevMed comboTango disclosed a 14% reduction in headcount even as the company shared more evidence that its PRMT5 inhibitor enhances Revolution Medicines’ Rasonque.fiercebiotech · 22d ago
- ESMO 2026: Tango trips on sinking response rates in pancreatic cancer but will move to Phase 3A combination of Tango Therapeutics’ vopimetostat and Revolution Medicines’ recently approved Rasonque led to a response rate of 82% in an ongoing Phase 1/2 trial—a drop from 92% that was reported…biospace · 24d ago
- Tango data add to growing momentum for pancreatic cancer drugsA combination involving Tango’s experimental therapy appeared to boost response rates in a small clinical trial well beyond what would be expected, sparking a share surge.biopharma_dive · 5mo ago
- STAT+: Pharmalittle: We’re reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and moreLilly disclosed new data that provide more details on the safety and tolerability of its next-generation obesity drug retatrutidestat · 5mo ago
- STAT+: Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rateA combination of pancreatic cancer drugs from Tango Therapeutics and Revolution Medicines led to a strong response rate in an early-stage trial.stat · 5mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that